Benzinga · Aug 10, 2026
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13
RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $12 to $13.
AR
NYSE · ARDT
Ardent Health Partners, LLC
Healthcare · Medical - Care Facilities
$10.99
Up+$0.51 (+4.87%)
Updated Aug 24, 2026, 2:33 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.34B
- P/E ratio
- 6.44
- Dividend yield
- 0.00%
- 52-week range
- $7.71 – $15.48
- Volume
- 239.14K
- Avg. volume
- 455.22K
Price performance
ARDT price history
1M range · 20 trading sessions · Daily adjusted prices
ARDT closed at $10.99 after 20 trading sessions, up 0.37% for the selected period.
- Last close
- $10.99
- Period change
- +0.37%
- Period low
- $10.48
- Period high
- $11.59
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $10.51 | $11.02 | $10.35 | $10.99 | 239.14K |
| Aug 20, 2026 | $10.58 | $10.74 | $10.40 | $10.48 | 237.65K |
| Aug 19, 2026 | $11.02 | $11.28 | $10.61 | $10.62 | 369.62K |
| Aug 18, 2026 | $11.03 | $11.08 | $10.85 | $10.93 | 274.73K |
| Aug 17, 2026 | $10.87 | $10.9599 | $10.80 | $10.89 | 220.03K |
| Aug 14, 2026 | $10.96 | $11.15 | $10.85 | $10.91 | 250.37K |
| Aug 13, 2026 | $11.18 | $11.32 | $10.94 | $11.02 | 244.82K |
| Aug 12, 2026 | $10.89 | $11.10 | $10.69 | $11.10 | 297.18K |
| Aug 11, 2026 | $11.13 | $11.315 | $10.955 | $10.97 | 323.31K |
| Aug 10, 2026 | $11.385 | $11.725 | $10.92 | $11.06 | 555.27K |
| Aug 7, 2026 | $11.56 | $11.89 | $11.46 | $11.55 | 339.81K |
| Aug 6, 2026 | $11.35 | $11.64 | $11.075 | $11.59 | 687.9K |
| Aug 5, 2026 | $11.51 | $11.63 | $10.54 | $11.16 | 1.02M |
| Aug 4, 2026 | $10.80 | $10.81 | $10.42 | $10.75 | 413.48K |
| Aug 3, 2026 | $10.77 | $10.91 | $10.61 | $10.75 | 412.59K |
| Jul 31, 2026 | $10.65 | $10.705 | $10.27 | $10.67 | 423.92K |
| Jul 30, 2026 | $10.90 | $11.085 | $10.63 | $10.73 | 452.73K |
| Jul 29, 2026 | $11.52 | $11.68 | $10.80 | $10.93 | 764.77K |
| Jul 28, 2026 | $11.11 | $11.60 | $11.11 | $11.47 | 608.22K |
| Jul 27, 2026 | $10.76 | $11.19 | $10.64 | $10.95 | 648.85K |
Latest ARDT news
The latest Smart Investors Daily articles mentioning ARDT.
Stock researchCompany · Overview
ARDT research
Overview
Company profile and research snapshot.
Company profile
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in services and technologies, Ardent is passionate about making healthcare easier to access.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.14
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | Guggenheim | Buy | — |
| Aug 6, 2026 | Truist Securities | Buy | — |
| Jul 14, 2026 | Truist Securities | Buy | — |
| Jul 9, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 8, 2026
Is Ardent Health (ARDT) Cheap On Lowered Guidance And Weaker Q2 Earnings?
Ardent Health earnings and guidance reset Ardent Health (ARDT) reported second quarter 2026 results on 4 August, with net income and earnings per share lower than a year earlier and full year earnings guidance reduced. The company paired this softer outlook with an update on its ongoing share buyback program, which has now retired more than 1.2% of outstanding shares. See our latest analysis for Ardent Health. Ardent Health shares have had a strong run in 2026, with a 33.68% year to date...
Yahoo · Aug 7, 2026
New Strong Sell Stocks for August 7th
ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.
Benzinga · Aug 6, 2026
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13
Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $12 to $13.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
